ChemoCentryx has initiatied Phase I clinical trials of CCX168, a novel orally administered small molecule designed to treat autoimmune diseases.
According to the company CCX168 is a highly potent and very selective compound that specifically targets the C5a receptor (C5aR), an important part of the inflammatory response associated with autoimmune diseases such as systemic lupus erythematosus, certain types of vasculitis, age-related macular degeneration and rheumatoid arthritis.
ChemoCentryx president and CEO Thomas J Schall said that the company had demonstrated the ability to develop a compound targeting C5aR, which has proved to be an enormous challenge for the pharmaceutical industry.
"As a result, we bring to clinical development a C5aR antagonist unlike any other compound that has been developed to date," Schall said.
The initiation of this Phase I trial triggered a $10m milestone payment from GlaxoSmithKline.